Published in N Engl J Med on January 16, 2003
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | NCT02766582
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Cancer immunotherapy comes of age. Nature (2011) 12.35
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 4.23
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys (2007) 3.87
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Principles of adoptive T cell cancer therapy. J Clin Invest (2007) 2.65
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell (2015) 2.63
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res (2011) 2.59
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res (2012) 2.11
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Immune regulation of cancer. J Clin Oncol (2010) 1.99
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 1.96
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer (2004) 1.80
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Ovarian cancer pathogenesis: a model in evolution. J Oncol (2009) 1.77
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity (2013) 1.77
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers. Cancer Epidemiol Biomarkers Prev (2012) 1.76
Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med (2013) 1.72
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity (2014) 1.69
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One (2014) 1.64
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell (2016) 1.62
Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer (2008) 1.62
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics (2011) 1.57
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med (2014) 1.55
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer (2011) 1.52
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer (2014) 1.51
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol (2012) 1.50
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Tumor immunosurveillance in human cancers. Cancer Metastasis Rev (2011) 1.48
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47
Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS One (2016) 1.40
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology (2013) 1.37
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
Regulatory T cells and tumour immunity - observations in mice and men. Immunology (2007) 1.34
Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol (2009) 1.34
Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol (2009) 1.33
Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med (2005) 1.33
Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther (2013) 1.33
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.32
Inherited determinants of ovarian cancer survival. Clin Cancer Res (2010) 1.32
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Cancer immunotherapy comes of age. Nature (2011) 12.35
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Laser-capture microdissection. Nat Protoc (2006) 3.80
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy. Gynecol Oncol (2003) 3.39
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Evolution of sleep quantity, sleep deprivation, mood disturbances, empathy, and burnout among interns. Acad Med (2006) 2.39
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Mechanisms of microRNA deregulation in human cancer. Cell Cycle (2008) 2.30
Assessing semantic similarity measures for the characterization of human regulatory pathways. Bioinformatics (2006) 2.29
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol (2004) 2.24
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Functional role and prognostic significance of CD157 in ovarian carcinoma. J Natl Cancer Inst (2010) 2.08
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004) 2.06
Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis (2003) 2.02
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res (2007) 2.01
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod Biol Endocrinol (2009) 1.92
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat (2008) 1.86
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Diagnosis of pelvic endometriosis with use of macroscopic versus histologic findings. Fertil Steril (2005) 1.80
Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society. J Pediatr Orthop B (2003) 1.78
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010) 1.78
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res (2006) 1.70
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70
Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res (2006) 1.69
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res (2008) 1.66
Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer (2004) 1.64
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res (2011) 1.62
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res (2003) 1.62
Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat (2012) 1.60
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res (2012) 1.51
Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood (2012) 1.49